首页> 外文期刊>Journal of Medical Radiation Sciences >Long-term outcomes following post-operative radiotherapy for Stage I/II testicular seminoma ?¢???? an Australasian single-institution experience
【24h】

Long-term outcomes following post-operative radiotherapy for Stage I/II testicular seminoma ?¢???? an Australasian single-institution experience

机译:I / II期睾丸精原细胞瘤放疗后的长期结局澳洲单一机构的经验

获取原文
           

摘要

Abstract Introduction The aim of the study is to review the long-term oncological outcomes and adverse effects of post-operative radiotherapy (PORT) for Stage I/II seminoma patients in an Australian radiation treatment centre. Methods This is a retrospective study of 125 patients with Stage I/II seminoma treated with PORT at the Alfred Health Radiation Oncology Service between 1992 and 2013. Patients were linked to the Victorian Cancer Registry to enable confirmation of survival and diagnosis of secondary malignancies (SM). The relapse-free survival (RFS), testicular-cancer-specific survival (TCSS), overall survival (OS) and SM-free survival (SMFS) were estimated with Kaplan?¢????Meier methods. Results The median age at diagnosis was 36 (range 20?¢????62). The median time between diagnosis and PORT was 1.6 months (range: 0.5?¢????4.5). Fifty patients (40%) had PORT to the para-aortic (PA) target alone, while the remaining had PORT to PA and ipsilateral or bilateral iliac lymph nodes. There were no acute adverse effects requiring admission. The median follow-up after PORT was 7.8 years (range = 0.1?¢????19.1). There were two relapses, both of which occurred within 1 year of PORT (estimated 10-year RFS = 98.4%). Five deaths were reported, none of which were testicular cancer-related death (estimated 10-year TCSS = 100%, 10-year OS = 97.3%). There were seven SM (one lower lip cancer, one upper shoulder melanoma, one mesothelioma, two prostate cancer, one acute myeloid leukaemia and one contralateral testicular seminoma) reported in six patients, with estimated 10-year SMFS of 92.9%. Conclusion Our series confirms excellent oncological outcomes among patients with Stage I/II seminoma treated with PORT, with uncommon occurrence of SM.
机译:摘要简介本研究的目的是回顾澳大利亚放射治疗中心I / II期精原细胞瘤患者的长期肿瘤学结果和术后放疗(PORT)的不良反应。方法这是一项回顾性研究,研究对象是1992年至2013年间在Alfred Health放射肿瘤学服务中心接受PORT治疗的125例I / II期精原细胞瘤患者。患者与维多利亚州癌症登记处联系,以确认生存和诊断继发性恶性肿瘤(SM )。无复发生存期(RFS),睾丸癌特异性生存期(TCSS),总生存期(OS)和无SM生存期(SMFS)用Kaplan?Meier方法评估。结果诊断时的中位年龄为36岁(范围为20 ¢ 62)。诊断到PORT的中位时间为1.6个月(范围:0.5≤4.5)。五十名患者(40%)仅具有到达主动脉旁(PA)目标的PORT,而其余患者具有PORT至PA和同侧或双侧淋巴结的PORT。没有需要入院的急性不良反应。 PORT术后的中位随访时间为7.8年(范围= 0.1±19.1)。有两次复发,都在PORT的1年内发生(估计的10年RFS = 98.4%)。据报道有五例死亡,其中没有一例是与睾丸癌相关的死亡(估计的10年TCSS = 100%,10年OS = 97.3%)。 6例患者中报告了7例SM(1个下唇癌,1个上肩黑素瘤,1个间皮瘤,2个前列腺癌,1个急性骨髓性白血病和1个对侧睾丸精原细胞瘤),估计10年SMFS为92.9%。结论我们的系列研究证实,接受PORT治疗的I / II期精原细胞瘤患者具有出色的肿瘤学结局,而且SM的发生率不高。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号